Unither Pharmaceuticals
Unither Pharmaceuticals is a French CDMO and world leader in Blow-Fill-Seal (BFS) sterile liquid manufacturing, operating 9 production sites across 4 continents with 5+ billion annual doses capacity, serving pharmaceutical companies from startups to large international firms.
- Company typePrivate
- Founded1993
- HeadquartersParis, France
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Unither Pharmaceuticals does
Unither Pharmaceuticals is a privately held French Contract Development and Manufacturing Organization (CDMO) founded in 1993 and headquartered in Paris. The company specializes in sterile and non-sterile liquid pharmaceutical forms, including single-dose, multi-dose, vials, liquid stick-packs, and sprays, and is self-identified as the world leader in Blow-Fill-Seal (BFS) technology, with an annual production capacity exceeding 5 billion doses across 9 production sites on four continents (France, United States, Brazil, China) and approximately 2,490 employees as of December 2025. Products are distributed to more than 100 countries.
Its core technology platform is BFS, a continuous aseptic process that combines polymer extrusion, container forming, filling, and sealing in a single automated operation under sterile air shower, producing sterile-by-construction unit-dose containers. The portfolio of proprietary platforms extends BFS into adjacent delivery formats: Euroject (BFS-based injectable for biologics), Sol-Gel (ophthalmic sustained-delivery gels), Uniflash (oro-mucosal delivery), and Carragelose (a CE-certified carrageenan-based nasal/ophthalmic antiviral platform acquired from Marinomed Biotech in November 2024 for up to EUR 20 million). Multi-dose containers with preservative or preservative-free formats, nasal/respiratory sprays, and pediatric-oriented liquid stick-packs round out the technology set.
Unither generates revenue through three principal streams: (1) CDMO contract manufacturing services spanning technology transfer, scale-up, clinical and commercial batch production for pharmaceutical clients; (2) co-development partnerships in which Unither collaborates with clients to design and industrialize new products; and (3) out-licensing of turnkey products and ready-to-register dossiers, including Carragelose, Euroject, Sol-Gel, and Uniflash, to pharmaceutical clients for marketing under their own brands. The company serves customers from start-ups to large international pharmaceutical firms across therapeutic areas including ophthalmology, ENT, injectable, respiratory, and rare diseases. Pricing is project-specific and quote-based. Recent strategic actions include the groundbreaking of a new industrial facility in Gannat, France (January 2026), the Carragelose acquisition (2024), the SeaBeLife joint development agreement for SBL03 in retinal disease (2025), and the appointment of Henrik Krüpper as CEO.
Unither Pharmaceuticals firmographics
Firmographics- Name
- Unither Pharmaceuticals
- Legal name
- UNITHER PHARMACEUTICALS SAS
- Website
- https://unither-pharma.com
- Company type
- Private
- Founded year
- 1993
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Unither Pharmaceuticals is a French CDMO and world leader in Blow-Fill-Seal (BFS) sterile liquid manufacturing, operating 9 production sites across 4 continents with 5+ billion annual doses capacity, serving pharmaceutical companies from startups to large international firms.
- Ownership category
- akta.pro rank
Unither Pharmaceuticals industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)
- akta.pro secondary industries
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
Keywords
Where Unither Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices10 records
Markets served
Unither Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Manufacturing Services: CDMO manufacturing services for clinical and commercial batches. Unither produces sterile and non-sterile liquid pharmaceuticals, BFS unit-doses, multi-dose containers, sprays, stick-packs, and vials for pharmaceutical clients from preclinical phases through commercial scale.
- Co-Development Partnerships: Collaborative product development model where Unither works closely with clients to design, develop, and industrialize new products, reducing time-to-market for innovative health solutions.
- Out-Licensing: Turnkey product solutions including ready-to-register product dossiers and licensed medical devices and drugs. Includes products like Carragelose, Euroject, Sol-Gel, and Uniflash offered for licensing to clients who can market under their own brand.
- Product Acquisition: Acquisition of product lines and businesses such as the Carragelose business from Marinomed Biotech AG for up to EUR 20 million, expanding Unither's product portfolio and market presence.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels9 records
Unither Pharmaceuticals product offering
Product offeringCore offering
Unither Pharmaceuticals is a French Contract Development and Manufacturing Organization (CDMO) that develops, formulates, and manufactures sterile and non-sterile liquid pharmaceutical dosage forms for other pharmaceutical companies. It is the world leader in Blow-Fill-Seal (BFS) technology for sterile single-dose manufacturing, with an annual production capacity exceeding 5 billion doses, and also offers multi-dose, spray, stick-pack, vial, and injectable formats alongside proprietary platforms such as Euroject, Carragelose, Sol-Gel, and Uniflash.
Product overview
Unither Pharmaceuticals is a Contract Development and Manufacturing Organization (CDMO) specializing in sterile and non-sterile liquid pharmaceutical forms. The company's core technology is Blow-Fill-Seal (BFS), the world's leading BFS platform with 5 billion annual dose capacity. Their product portfolio includes BFS single doses, multi-dose containers, sprays, liquid stick-packs, and vials. Breakthrough solutions include Euroject (BFS injectable), Carragelose (viral protection), Sol-Gel (ophthalmology), and Uniflash (oro-mucosal). Services span manufacturing (technology transfer, scale-up, commercial batches, rare disease and veterinary), development (formulation, analytical, clinical, stability, regulatory), and out-licensing of turnkey products. Therapeutic applications focus on ophthalmology, ENT, injectable, respiratory, and rare diseases.
Differentiator
Problem solved
Functional benefit
Brands
- Euroject®: BFS-based injectable drug delivery device for unit-dose injection of biologics
- Carragelose®
- Sol-Gel™
- Uniflash®
- InnoSphère
- Inspire Hub
Products and services
- Pharmaceutical Manufacturing Services
Quantifiable outcome
- Annual production capacity exceeding 5 billion doses using BFS technology
- +3 more outcomes
Companies that use Unither Pharmaceuticals
Customer profileNamed customers1 record
Segments5 records
Ideal customer profiles3 records
Unither Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Unither Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- Université Paris Cité, CNRS, INSERM, and other academic institutionsminorCollaborative research partnership with Unither Développement Bordeaux on scientific publications regarding ophthalmology, including research on polyunsaturated fatty acids and age-related macular degeneration published in the International Journal of Molecular Sciences.
- Eyecelerator and Ora, Inc.minorCollaboration on 'Eye to Market' web series exploring how ophthalmic innovations move from scientific development to real-world patient adoption. Series features expert interviews on translational research, clinical development, manufacturing, regulatory strategy, and market access. Published on Eyecelerator YouTube channel targeting innovators, clinicians, investors, and industry leaders.
- SeaBeLifecoreJoint development agreement for SBL03, a topical ophthalmic drug candidate for treating degenerative retinal disorders such as geographic atrophy and dry age-related macular degeneration. Unither handles pharmaceutical development, industrial scale-up, and GMP batch manufacturing. Clinical trials planned for 2027. SeaBeLife retains ownership of the drug candidate while Unither provides manufacturing expertise.
- Marinomed Biotech AGcoreAcquisition of Marinomed's Carragelose business for up to EUR 20 million based on target achievement. Carragelose is a viral infection protection platform based on carrageenan technology. Proceeds fund Marinomed's restructuring and growth in its Marinosolv platform.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
Unither Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Catalent: Catalent is one of the largest global CDMOs with a broad service portfolio spanning oral, injectable, and biologic drug delivery. Comparable to Unither as a direct CDMO competitor for sterile fill-finish and injectable manufacturing, though at a much larger scale and broader therapeutic reach.
- Lonza Group: Lonza is the world's largest CDMO by revenue, offering mammalian and microbial biologics manufacturing as well as fill-finish services. Directly comparable to Unither in sterile injectable and biologic fill-finish, with substantially larger scale and a broader technology portfolio.
- Becton, Dickinson and Company (BD): BD Medical Pharmaceutical Systems is a global manufacturer of prefilled syringes, auto-injectors, and BFS-based delivery systems for injectables. Comparable to Unither as a competing supplier of sterile unit-dose and injectable delivery platforms, though BD focuses on device manufacturing rather than CDMO services.
Direct peers
- Recipharm: Recipharm is a European-headquartered CDMO focused on sterile fill-finish, inhalation, and biologics. Comparable to Unither in providing B2B contract sterile manufacturing to pharma companies, with similar geographic reach across Europe and overlapping capabilities in ophthalmic and injectable CDMO services.
- Fareva: Fareva is a French-headquartered CDMO with sterile injectable, ophthalmic, and topical manufacturing capabilities. Highly comparable to Unither as a fellow French sterile and ophthalmic CDMO serving multinational pharma clients with similar CDMO service offerings.
- Delpharm: Delpharm is a leading French CDMO offering sterile and non-sterile manufacturing services to pharma companies across Europe. Directly comparable to Unither as a French-headquartered contract manufacturer serving multinational pharma with liquid and sterile dosage form capabilities.
- Aenova Group: Aenova is a European CDMO providing sterile and non-sterile manufacturing including softgel capsules, sterile liquids, and injectables. Comparable to Unither as a European-based contract manufacturer with overlapping capabilities in sterile liquid pharmaceutical manufacturing for global pharma clients.
- Rommelag: Rommelag is a German specialist in Blow-Fill-Seal (BFS) aseptic packaging technology for pharmaceuticals. The closest direct peer to Unither in BFS technology, also serving pharma clients with aseptic unit-dose manufacturing; together they constitute the leading global BFS CDMO duopoly.
- Kindeva Drug Delivery: Kindeva Drug Delivery is a global CDMO specializing in inhalation, injectable, and transdermal drug delivery, with BFS and aseptic fill-finish capabilities. Directly comparable to Unither as a CDMO serving pharma clients with sterile unit-dose and injectable manufacturing across multiple sites.
Emerging players
- Stevanato Group: Stevanato Group is an Italian manufacturer of glass primary packaging and integrated fill-finish solutions for injectable drugs. Comparable to Unither in sterile injectable manufacturing services, with growing pharma services offerings adjacent to Unither's Euroject BFS injectable platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Unither Pharmaceuticals social profiles
Digital presenceUnither Pharmaceuticals compliance and trust
Trust signalCompliance14 records
Unither Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Unither Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles4 records
Unither Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries9 records
Unither Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Unither Pharmaceuticals M&A and investment
M&A and investmentM&A2 records
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Unither Pharmaceuticals
What does Unither Pharmaceuticals do?
Unither Pharmaceuticals is a French Contract Development and Manufacturing Organization (CDMO) that develops, formulates, and manufactures sterile and non-sterile liquid pharmaceutical dosage forms for other pharmaceutical companies. It is the world leader in Blow-Fill-Seal (BFS) technology for sterile single-dose manufacturing, with an annual production capacity exceeding 5 billion doses, and also offers multi-dose, spray, stick-pack, vial, and injectable formats alongside proprietary platforms such as Euroject, Carragelose, Sol-Gel, and Uniflash.
Is Unither Pharmaceuticals a public or private company?
Unither Pharmaceuticals is a private company. It is classified as private equity controlled and is currently operating.
When was Unither Pharmaceuticals founded?
Unither Pharmaceuticals was founded in 1993. It employs 1,001 to 5,000 people.
Where is Unither Pharmaceuticals based?
Unither Pharmaceuticals is headquartered in Paris, France, in the Europe region.
How does Unither Pharmaceuticals make money?
Four revenue lines are on record. Contract Manufacturing Services are the primary driver. The others are co-Development Partnerships, out-Licensing and product Acquisition.
Who are Unither Pharmaceuticals's main competitors?
Broad incumbents on record are Catalent, Lonza Group and Becton, Dickinson and Company (BD). Direct peers are Recipharm, Fareva, Delpharm, Aenova Group, Rommelag and Kindeva Drug Delivery. Stevanato Group is listed as an emerging player.
Does Unither Pharmaceuticals have an API?
No public API is recorded for Unither Pharmaceuticals.
What industry is Unither Pharmaceuticals in?
Unither Pharmaceuticals's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.